Abstract
The use of intravenous immunoglobulin is standard practice for antibody replacement in the humoral immunodeficiency diseases. Most infusions proceed uneventfully, but a proportion of infusions (5–8%) produces some degree of an infusion reaction. While the cause of most of these infusion reactions is unknown, an established, but rare cause of reactions is IgA antibodies in the serum of the patient, which apparently forms an immune complex with the traces of IgA in the infused immunoglobulin. This article describes our studies of five immunodeficient patients who had high-titered anti-IgA antibodies and a history of severe infusion reactions to intravenous immunoglobulin products not depleted of IgA (IgA content, 270–720 µg/ml). Over a 6-year period we gave these patients IgA-depleted intravenous immunoglobulin for a total of 170 infusions. These infusions were generally well tolerated; however, mild to moderate infusion reactions did occur in 9 of the 170 infusions (5.3%). These reactions were not related to the IgA content of the immunoglobulin solutions used—ascertained to vary between 0.4 and 2.9 µg/ml of IgA. Levels of plasma C3a and C4a increased after immunoglobulin infusions but the appearance of these components was not accompanied by any infusion reaction. We conclude that the long-term infusions of IgA-depleted intravenous immunoglobulin, within the range of IgA concentrations investigated, into patients with even very high-titered antibodies to IgA, is a safe practice.
Similar content being viewed by others
References
Vyas GN, Perkins HA, Fudenberg HH: Anaphylactoid transfusion reaction associated with anti-IgA. Lancet 2:312–314, 1971
Schmidt AP, Taswell HF, Gleich GJ: Anaphylactic transfusion reactions associated with anti-IgA antibody. N Engl J Med 280:188–193, 1969
Rivat I, Rivat C, Daveau M, Ropartz C: Comparative frequencies of anti-IgA antibodies among patients with anaphylactic transfusion reactions and among normal blood donors. Clin Immunol Immunopathol 7:340–348, 1977
Wells JV, Buckley RH, Schanfield MS: Anaphylactoid reactions to plasma infusions in patients with hypogammaglobulinemia and anti-IgA antibodies. Clin Immunol Immunopathol 8:265–271, 1971
Hammarström L, Persson MAA, Smith CIE: Anti-IgA in selective IgA deficiencyin vitro effects and Ig subclass patterns of human anti-IgA. Scand J Immunol 18:509–513, 1983
Ferreira A, Garcia-Rodriguez MC, Lopez-Trascasa M, Pascual-Salcedo D, Fontan G: Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol 47:199–207, 1988
Oxelius VA, Laurell AB, Lindqvist B, Golebiowska M, Axelsson U, Björkander J, Hanson LÅ: IgG subclasses in selective IgA deficiency. Importance of IgG2-IgA deficiency. N Engl J Med 302:1476–1477, 1981
Oxelius VA: Immunoglobulin (IgG) subclasses and human disease. Am J Med 76:7–18, 1984
Björkander J, Hammarström L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LÅ: Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 7:8–15, 1987
Cunningham-Rundles C, Wong S, Björkander J, Hanson LÅ: Use of an IgA-depleted intravenous immunoglobulin in a patient with an IgA antibody. Clin Immunol Immunopathol 38:141–9, 1986
Björkander J, Bengtsson U, Oxelius VA, Hanson LÅ: Symptoms in patients with lowered levels of IgG subclasses, with or without IgA deficiency and effects of immunoglobulin prophylaxis. Monogr Allergy 20:157–163, 1986
Hugli TE, Chenoweth DF: Biologically active peptides of complement: Techniques and significance of C3a and C5a measurements.In Laboratory and Research Methods in Biology and Medicine, RM Nakamusa, WR Dito (eds.), New York, Alan R. Liss, 1980, p 443
Day NK, Good RA, Wahn V: Adverse reaction in selected patients following intravenous infusions of gammaglobulin. Am J Med Suppl 3A:25–31, 1984
Barandun S, Morrell A: Adverse reactions to immunoglobulin preparations.In Immunohemotherapy, UE Nydegger (ed). London, Academic Press, 1981, pp 223–230
Cunningham-Rundles C, Siegal FP, Smithwick EM, Cunningham-Rundles S, Lion-Boule A, O'Malley J, Barandun S, Good RA: Efficacy of intravenous gammaglobulin in humoral immunodeficiency disease. Ann Intern Med 101:435–439, 1984
Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantman HJ, Nelson J, Ochs H, Stiehm ER, Tiller T, Wara DW, Wedgewood R: Use of intravenous gammaglobulin in antibody immunodeficiency: Results of a multicenter controlled trial. Clin Immunol Immunopathol 22:60–67, 1982
Stiehm ER, Ashida E, Kim KS, Winston DJ, Haas A, Gale RP: Intravenous immunoglobulin as therapeutic agents. Ann Intern Med 107:367–382, 1987
Cunningham-Rundles C, Carr RI: Dietary bovine antigens and immune complex formation after intravenous immunoglobulin in common variable immunodeficiency. J Clin Immunol 6:381–388, 1986
Zilow G, Sturm JA, Rother U, Kirschfink M: Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 79:151–157, 1990
Sundsmo JS, Papin RA, Wood L, Hirani S, Waldeck N, Buckingham B, Kershnar A, Ascher M, Charles MA: Complement activation in Type 1 human diabetes. Clin Immunol Immunopathol 35:211–225, 1985
Hakim RM, Breillatt J, Lazarus MJ, Port F: Complement activation and hyper-sensitivity reactions to dialysis membranes. N Engl J Med 311:878–882, 1984
Cunningham-Rundles C, Day NK, Wahn V, Smithwick EM, Siegal FP, Gupta S, Good RA: In Reaction to Intravenous Gammaglobulin Infusions and Immune Complex Formation, Immunohemotherapy, UE Nydegger (ed). London, Academic Press, London, 1981, pp 447–449
Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. N Engl J Med 314:560–562, 1986
Romer J, Morgenthaler JJ, Scherz R, Skvaril F: Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 42:62–73, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cunningham-Rundles, C., Zhou, Z., Mankarious, S. et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 13, 272–278 (1993). https://doi.org/10.1007/BF00919386
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00919386